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Abstract
Background: Sexual dysfunction (SD) is very common in people with multiple sclerosis (PwMS) and contributes a
significant burden of disease, particularly for young people. SD has direct neurological contributions from
depression and fatigue, which occur commonly in PwMS. Modifiable factors may represent potential targets for
treatment and prevention of SD. We aimed to assess the prevalence of SD and explore associations between SD
and demographic and modifiable risk factors, as well as depression and fatigue in a large cohort of PwMS.
Methods: We analysed self-reported data from a large, international sample of PwMS recruited via Web 2.0
platforms, including demographic, lifestyle and disease characteristics. Specific sexual function questions included 4
items from the sexual function scale and 1 item regarding satisfaction with sexual function, part of the MS Quality
of Life-54 instrument.
Results: 2062 PwMS from 54 countries completed questions on sexual function. 81.1 % were women, mean age
was 45 years, most (62.8 %) reported having relapsing-remitting MS. The majority (54.5 %) reported one or more
problems with sexual function and were classified as having SD. Lack of sexual interest (41.8 % of women), and
difficulty with erection (40.7 % of men) were most common. The median total sexual function score was 75.0 out of
100, and 43.7 % were satisfied with their sexual function. Regression modeling revealed independent associations
between sexual function and satisfaction and a range of demographic factors, including age, as well as depression
risk, antidepressant use, and fatigue in PwMS.
Conclusion: This cross-sectional study shows that SD and lack of satisfaction with sexual function are associated
with depression risk and fatigue, as well as modifiable lifestyle factors diet and physical activity (after adjusting for
depression and fatigue). Planned longitudinal follow-up of this sample may help clarify these associations and the
underlying mechanisms. There is potential to prevent and treat SD in PwMS by addressing depression and fatigue
and their determinants. Clinicians and PwMS should be aware of SD and associated factors as part of a
comprehensive preventive approach to managing MS.
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Background
Multiple sclerosis (MS) is the most common disabling
condition of young adults with myriad potential effects
on neurological function, including sensory and auto-
nomic function [1]. Subtle neurological disturbances can
directly affect sexual function at a time of life when it as-
sumes particular importance for many people. MS can
also affect sexual function indirectly through other phys-
ical disabilities such as spasticity or bladder dysfunction,
as a side effect of medications and through psychosocial
mechanisms such as the presence of depression [2]. Dis-
turbed sexual function can have detrimental effects
particularly on partner relationships and mental health-
related quality of life, well demonstrated in a large North
American Research Committee on Multiple Sclerosis
(NARCOMS) Registry sample of 6,183 PwMS [3].
Sexual dysfunction (SD) is very common in people
with MS (PwMS). In reviewing seven prior studies with
a total of 455 women and 326 men with MS, a 1995 re-
view reported a prevalence of 33–75 % for females and
47–75 % for males [4]. This review has often been cited
in subsequent papers as a prevalence of 40 to 80 % for
females and 50 to 90 % for males [5–9]. More precise
prevalence of SD is difficult to determine due to incon-
sistent definitions. The need for standard definitions has
been recognised and specific indices proposed [10–12].
These include definitions for sexual arousal disorders in
women, erectile dysfunction in men, orgasmic dysfunc-
tion and dyspareunia. There is not, however, a consistent
definition in the literature for the diagnosis of SD [9].
According to the World Health Organization (WHO),
SD is a syndrome that includes one or more of: lack or
loss of sexual desire, sexual aversion and lack of sexual
enjoyment, failure of genital response (erectile dysfunc-
tion in men and vaginal dryness or failure of lubrication
in women), orgasmic dysfunction, premature ejaculation,
vaginismus and dyspareunia [13].
It has been proposed that MS can affect sexual func-
tion through a variety of mechanisms, both direct and
indirect [7, 14–18], however the exact aetiology is still a
matter of debate [7, 9, 16, 19]. Primary SD refers to dir-
ect impairment of sexual responses or feelings by neuro-
logical damage in the central nervous system. This may
lead to symptoms such as erectile dysfunction, anorgas-
mia and decreased sensation. Secondary SD is when
physical changes indirectly affect sexual responses, unre-
lated to specific nerve pathways to the genitals, includ-
ing fatigue, muscle tightness, spasticity or weakness and
bladder or bowel dysfunction. Tertiary SD relates to psy-
chosocial issues associated with body image, emotional
challenges and cultural influences, including the com-
monly experienced effects of depression on sexual func-
tion and low self-esteem that indirectly affect sexual
function [8, 9, 16, 19–21]. Several studies have identified
demographic variables associated with sexual dysfunc-
tion, including age, number of children, education, and
relationship duration, while disease characteristics such
as level of disability, duration and type of MS also play a
role [21–23].
The importance of SD to the quality of life of PwMS
and its association with depression has been highlighted
in previous research [24], but there is little knowledge
about potentially modifiable lifestyle determinants of
sexual function and dysfunction for PwMS. This study
aimed to assess prevalence of SD and satisfaction with
sexual function in an international sample of PwMS re-
cruited online as part of the Health Outcomes and Life-
style In a Sample of people with Multiple sclerosis
(HOLISM) study. We aimed to assess the associations of
disease characteristics, fatigue, depression risk and
demographics with sexual function and satisfaction, and
explore potential independent associations with modifi-
able lifestyle factors.
Methods
Participants and data collection
The methodology of the HOLISM study has previously
been described in detail [25]. In brief, participants were
recruited via online platforms, including social media,
websites and forums that engaged people with MS, most
of which had a health and lifestyle focus. The web-based
tool, SurveyMonkey®, was used to provide respondents
with a participant information sheet, an electronic con-
sent indicator, and the survey itself. Inclusion criteria
were adults of 18 years of age or more, self-reporting a
formal diagnosis of MS by a medical doctor. As the sur-
vey was in English, only English speaking participants
were included. Contact details were recorded for
planned longitudinal follow up.
Ethics, consent and permissions
The Health Sciences Human Ethics Sub-Committee at
the University of Melbourne provided ethical approval
for the study (Ethics ID: 1545102). Participants were
asked to read the participant information and to consent
before entering the survey.
Data collected and tools used
The online survey used validated tools where possible,
and took approximately 40 min to complete. Specific to
this study were items exploring demographic variables,
morbidity indicators and modifiable lifestyle factors.
Sexual function and satisfaction
The Multiple Sclerosis Quality Of Life (MSQOL-54) sex-
ual function scale and satisfaction item were used to as-
sess these variables. The sexual function scale consists of
4 items regarding: lack of sexual interest, difficulty with
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erection (for men)/lubrication (for women), difficulty
having orgasm, and ability to satisfy a sexual partner.
These items had a drop-down menu with 4 options (and
corresponding score): “not a problem” (100), “a little of a
problem” (66.6), “somewhat of a problem” (33.3), and
“very much a problem” (0). These scores are added and
divided by the number of items which gives rise to the
sexual function score of 0–100, if 2 or more items were
completed. We categorised participants as having SD
when “somewhat of a problem” or “very much a prob-
lem” was selected in response to one or more of the four
items, and 2 or more out of the 4 items were completed.
In addition, satisfaction was assessed with a single item:
“Overall, how satisfied were you with your sexual func-
tion during the past 4 weeks?” which had a drop-down
menu with 5 options which were merged in two categor-
ies: “satisfied” (comprising “very satisfied” and “some-
what satisfied”) and “not satisfied” (comprising “neither
satisfied nor dissatisfied”, “somewhat dissatisfied” and
“very dissatisfied”).
Demographic factors
Demographic factors were collected using researcher-
devised items and included age, gender, marital status,
number of children, educational status, and occupational
status.
Morbidity indicators
Health-related Quality of Life (HRQOL) was assessed by
the widely used MSQOL-54, giving rise to the mental
and physical composite scores, the sexual function scale,
as well as several other scales that were not included in
these analyses. Level of gait disability was assessed using
the Patient Determined Disease Steps (PDDS), a self-
reported surrogate tool to the Expanded Disability Status
Scale (EDSS), which has ordinal scores from 0 (no dis-
ability) to 8 (bed-bound). Researcher-devised items
assessed self-reported doctor-diagnosed relapse rate and
type of MS currently diagnosed. A list of 24 disease-
modifying drugs (DMDs) was provided and participants
were categorised as either currently using a DMD, or
not, and in addition participants were asked if they were
currently using antidepressants.
Modifiable Lifestyle factors
Height and weight information allowed calculation of body
mass index (BMI) according to the World Health
Organisation (WHO) criteria (<20 = underweight, 20–25 =
normal weight, 25–30 = overweight and >30 = obese). Diet-
ary habits were assessed with the Dietary Habits Question-
naire (DHQ) on a scale of 0–100. The International
Physical Activity Questionnaire (IPAQ) was included to as-
sess level of regular physical activity (low, moderate and
high). Omega-3 and vitamin D supplementation (yes/no),
meditation practice (never, ≤once a week, >once a week),
level of alcohol consumption (low (<15 g/week), moderate
(up to 30 g/day for females; up to 45 g/day for men), or
high) and current smoking status (yes/no) were assessed
using researcher-devised items. All data were self-reported.
Data analysis
Data were analysed using Stata 13 (StataCorp. 2013).
Continuous data were summarised using mean (standard
deviation) or median (interquartile range), and categor-
ical data using number (percentage).
Multivariable logistic regression models were used to in-
vestigate factors associated with SD and satisfaction with
sexual function. Multivariable linear regression modeling
was used to investigate factors associated with sexual
function score. Models were built using forward variable
selection [26]. Variables explored included stable demo-
graphic factors, clinical factors and modifiable lifestyle fac-
tors: age (continuous), gender, marital status, number of
children, employment status, education status, level of dis-
ability, current use of disease modifying drug, current use
of antidepressants, depression screen, clinically significant
fatigue, smoking status, level of alcohol use, level of phys-
ical activity, omega 3 supplementation, vitamin D supple-
mentation, meditation frequency, body mass index, and
dietary score.
Odds ratios and 95 % CIs are reported for logistic re-
gression and coefficients and 95%CI are reported for lin-
ear regression. We used complete case analyses, that is
analyses restricted to available data.
Results
Participation, demographics, and sexual function
Of 2469 survey respondents with confirmed MS, a total
of 2062 completed sexual function items enabling deriv-
ation of a sexual function scale score and categorization
of SD (yes/no). Demographic and clinical variables are
described in Table 1.
A comparison of those completing sexual function
items (to yield a total score) and those not complet-
ing this part of the MSQOL-54 revealed participants
were more likely to complete sexual function items if
they were younger (mean age 45.0 vs 48.0, p < .001),
more recently diagnosed (mean years since diagnosis
8.5 vs 9.4, p = .028), male (completed: male, 95.3 % vs
female, 87.7 %, p < .001), and partnered (completion:
88.9 %, vs single, 68.8 %; separated/divorced/widowed,
70.4 %; p < .001).
Overall, 54.5 % (1123, 95 % CI 52.3–56.6 %) were cate-
gorised as having SD (49.7 % of men and 55.6 % of
women, p = .036). Lack of sexual interest was somewhat
or very much a problem for 39.6 % (29.8 % of men and
41.8 % of women, p < .001); difficulty with erection or lu-
brication was somewhat or very much a problem for
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32.8 % (40.7 % of men and 30.9 % of women); 34.9 % re-
ported that having an orgasm was somewhat or very
much a problem (30.1 % of men and 36.0 % of women,
p = .029); and 21.5 % said that satisfying a sexual partner
was somewhat or very much a problem (28.9 % of men
and 19.7 % of women, p < .001). For the single item on
overall satisfaction, close to half the sample (n = 889,
43.7 %) were satisfied or very satisfied with their sexual
function in the previous 4 weeks, with no significant
gender difference. Those with SD were less likely to be
satisfied compared to those without SD (23.9 % vs
76.1 %, p < .001). The median total sexual function score
for the entire sample was 75.0 (IQR 41.7–91.7); and the
mean was 66.3 ([95 % CI 65.0–67.7]).
Sexual dysfunction
Variables that showed significant unadjusted associations
with SD were age, gender, marital status, children, em-
ployment, education, disability, depression, antidepres-
sant use, fatigue, smoking status, level of alcohol use,
level of physical activity, omega 3 supplementation, fre-
quency of meditation, BMI and diet score. The final re-
gression model (Table 2) showed that screening positive
for depression, clinical fatigue, being older, being retired
due to age or disability and using an antidepressant were
each factors associated with higher odds for SD. Not
having a partner and having a healthier diet were associ-
ated with lower odds for SD.
Satisfaction with sexual function
Variables that showed significant unadjusted associations
with satisfaction with sexual function were age, gender,
employment, disability, depression, use of antidepres-
sants, fatigue, smoking status, level of alcohol use, level
of physical activity, omega 3 supplementation, BMI and
diet score. The final regression model (Table 3) showed
that increasing age, screening positive for depression,
clinical fatigue, and using antidepressants were associ-
ated with lower odds, while having a high level of phys-
ical activity was associated with higher odds of being
satisfied with sexual function.
Sexual function scale
Variables that showed significant unadjusted associations
with sexual function score were age, gender, marital sta-
tus, number of children, employment, level of education,
disability, depression, antidepressant use, fatigue, smok-
ing status, level of alcohol use, level of physical activity,
omega 3 supplementation, BMI and diet score The final
regression model (Table 4) showed that increasing age,
being moderately or severely disabled, being retired due
to age or disability, screening positive for depression,
clinically significant fatigue and antidepressant use were
independently associated with a lower score on the sex-
ual function scale, while not having a partner, and having
a high level of physical activity was associated with a
higher score.
Subgroup analyses
Further analyses were performed with the above regres-
sion analyses repeated for only the subgroup with a
Table 1 Demographic and clinical variables
Demographic and clinical variables Na (%)
Gender Female 1663 (81.1)
Male 388 (18.9)
Age groups 18–39 years 648 (32.4)
40–49 years 665 (33.2)
>49 years 690 (34.4)
Country of residence United States of America 691 (33.5)
Australia 526 (25.5)
United Kingdom 339 (16.4)
51 other countries 506 (24.5)




Children None 611 (30.0)
One or more 1424 (70.0)
Education High school or below 498 (24.3)
Vocational training 338 (16.5)
University 1218 (59.3)
Employment Part or full time employed 1127 (54.8)




Type of MS Relapsing remitting 1290 (62.8)
Primary progressive 140 (6.8)
Secondary progressive 225 (11.0)
Other/unknown 398 (19.4)
Years since diagnosis (Median and interquartile
range)
6 (3–12)
Level of disability None-mild 1151 (56.2)
Moderate 698 (34.1)
Severe 200 (9.8)
Clinical fatigue Yes 1255 (65.7)
No 656 (34.3)
Positive screen for depression Yes 377 (19.0)
No 1607 (81.0)






aN varies due to non-completion
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partner. As results did not differ meaningfully from the
full case analysis, we do not report these findings here.
Discussion
Sexual function is an important issue for PwMS. Young
adults with MS particularly may see SD as the most
negative feature of the illness, given the variety of distur-
bances of sexual function, and the indirect effects on
mental health, quality of life and intimate relationships,
at a time of life when sexual activity may be at a peak
and seen as particularly important. Sexual function is
however often not a standard part of the consultation
with healthcare professionals for PwMS [27], despite
calls for its inclusion [28–30], and is therefore frequently
underdiagnosed [31].
Our data on a large sample of PwMS world-wide con-
firmed that SD is common, with over half of the sample
reporting one or more problems with sexual function,
and that SD is associated with lower satisfaction with
sexual function. Lack of sexual interest was the most
Table 2 Factors associated with sexual dysfunction
Variable Category Adj OR P 95 % CI
Age 1.03 <0.001 1.01 1.04
Gender Female Ref
Male 0.77 0.063 0.59 1.01
Marital status Married/cohabiting/ partnered Ref
Single 0.51 <0.001 0.35 0.75
Separated/divorced/widower 0.37 <0.001 0.26 0.53
Number of children 0 Ref
1 1.40 .058 .99 1.98
2 1.19 .262 .88 1.59
3 or more 0.72 .061 0.52 1.02
Employment Employed full or part time Ref
Student or stay at home carer 1.17 0.380 0.83 1.65
Unemployed 0.95 0.816 0.63 1.44
Retired due to age or disability 1.54 0.005 1.14 2.10
Level of disability No or some disability Ref
Gait/cane disability 1.29 0.053 1.00 1.67
Major mobility support 1.00 0.988 0.65 1.55
Clinically significant fatigue No Ref
Yes 1.61 <0.001 1.26 2.05
Depression screen Negative Ref
Positive 1.92 <0.001 1.42 2.60
Smoking status Never smoked Ref
Previously smoked 1.08 0.506 0.86 1.35
Current smoker 1.38 0.083 0.96 1.98
Physical activity Low active Ref
Moderate active 0.93 0.557 0.71 1.20
High active 0.91 0.509 0.69 1.20
Body mass index Normal Ref
Underweight 0.64 0.102 0.37 1.09
Overweight 0.93 0.601 0.72 1.21
Obese 1.26 0.125 0.94 1.70
Dietary score (0–100) 0.99 0.023 0.98 1.00
Prescription anti-depressant use No Ref
Yes 1.43 0.010 1.09 1.89
N = 1720, LR CHI2(23) = 262.6, p < .001, Pseudo R-squared = .111
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common problem in women while difficulty with
erection was the most common in men. The preva-
lence of SD in our study was lower than in previous
reports. One study found that 73.1 % of PwMS re-
ported one or more sexual disturbances. This was
nearly double compared to those with other chronic
diseases (39.2 %) and many times higher than healthy
controls (12.8 %) [7]. Others suggest a higher preva-
lence in the general population, at about 40–45 % of
women and 20–30 % of men [11]. However, defini-
tions are not directly comparable between studies,
and our sample is not likely to be representative of
the general MS population. It is probable that our
sample would have lower levels of SD than other
studies given that our sample was notably young, ed-
ucated and had a lower level of disability [25].
For the sexual function scale of the MSQOL-54 score,
we showed significant independent associations with
age, marital status, employment status, level of disability,
physical activity, clinical fatigue, screening positive for
depression and antidepressant use. Age, depression, anti-
depressant use, fatigue, and level of physical activity
were also independent predictors associated with satis-
faction with sexual function. Similarly, clinical fatigue,
depression and antidepressant use were independent de-
terminants of the presence of SD, along with age, mari-
tal, and employment status, as well as the modifiable
factor, diet.
This suggests that sexual function and dysfunction for
PwMS have very complex determinants related to an
interplay of individual, lifestyle and disease characteris-
tics, strongly influenced by the presence of depression,
the use of antidepressants, and fatigue. We have previ-
ously demonstrated modifiable lifestyle factors are im-
portant predictors in their own right of fatigue [32] and
depression risk [33], and may therefore indirectly affect
sexual function and satisfaction with sexual function.
Here, we were able to demonstrate that diet and level of
physical activity are associated with these outcomes even
after adjusting for other relevant factors.
Although smoking showed significant unadjusted as-
sociations with our outcomes, in the final regression
models, it did not reach a significance level of <.05.
Smoking has previously been linked with erectile dys-
function [34], probably mediating its effects via
microvascular circulatory impairment, although the
mechanism in women has not been well studied.
Regular exercise would likely counteract this mechan-
ism, and our data suggest an association with sexual
function score, and satisfaction with sexual function
after adjusting for depression and fatigue. Similarly,
better diet may have beneficial effects directly on the
microvasculature, but also improve satisfaction with
sexual function through indirect effects such as ameli-
oration of metabolic syndrome, known to have ad-
verse effects on sexual function [35, 36].
Table 3 Factors associated with satisfaction with sexual function
Adj OR P 95 % CI
Age 0.98 <0.001 0.96 0.99
Gender Male Ref
Female 1.12 0.401 0.86 1.45
Employment Employed full or part time Ref
Student or stay at home carer 0.90 0.509 0.64 1.24
Unemployed 1.14 0.519 0.77 1.69
Retired due to age or disability 0.85 0.262 0.63 1.13
Level of disability No or some disability Ref
Gait/cane disability 0.82 0.106 0.64 1.05
Major mobility support 0.92 0.711 0.61 1.40
Clinically significant fatigue No Ref
Yes 0.72 0.006 0.58 0.91
Depression screen Negative Ref
Positive 0.49 <0.001 0.37 0.66
Physical activity Low active Ref
Moderate active 1.24 0.093 0.97 1.59
High active 1.61 <0.001 1.23 2.09
Prescription anti-depressant use Yes 0.72 0.014 0.56 0.94
No Ref
N = 1754. LR CHI2(12) = 163.95, p < .001. PseudoR-squared = .0683
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To our knowledge, only two studies have thus far dis-
cussed the effect of lifestyle modification on SD [11, 37].
These studies suggest that increasing physical activity
improves symptoms of SD, however it is possible that
positive effects of exercise on mood mediated the ob-
served improvements. Our data suggest these effects are
independent determinants of SD. Modifying other fac-
tors such as smoking, obesity and alcohol consumption
may also improve SD if managed early in life, before
middle age [37].
SD is very common in people with depression in
the general population, who have a 50 to 70 % risk
[24]; this relationship appears to be bi-directional, in
that people with SD have a greatly heightened risk of
depression [24]. As depression occurs very commonly
in PwMS [38, 39], with a lifetime prevalence of
around 50 % [40], this contributes to the very high
prevalence of SD in PwMS. A number of studies have
shown that quality of life with respect to SD is lower
in PwMS who have depression [21, 39]. PwMS should
be screened for depression as early prevention and
treatment of depression has many benefits including a
potential benefit for people who experience SD [39].
However, antidepressant use was clearly associated
with the presence of sexual dysfunction, lower odds
for satisfaction with sexual function and lower sexual
function score, independent of the other factors in-
cluding screening positive for depression.
Fatigue also has a complex relationship with depres-
sion, and so may be expected to be associated with SD
for PwMS. Our study however confirmed associations
with the outcomes that were independent of and add-
itional to the associations with depression. Fatigue has
been shown to be significantly associated with SD in a
number of studies [16, 19, 23, 29, 41]. A significant rela-
tionship was found between SD and the presence of
physical disorders impeding sexual activity, in particular
fatigue [20], and although reported by people with a
range of chronic disease, appears to be a particular prob-
lem for PwMS [7].
Associations between SD and various MS-related clin-
ical and socio-demographic variables have been investi-
gated in other studies [19, 20, 23, 42]. Meaningful
correlations were found between SD and age, male gen-
der, low education level, unemployment, length of dis-
ease, length of marriage, anxiety, age of husband,
physical ability, cognitive deterioration, length of medi-
cation use, primary progressive MS, frequency of
Table 4 Factors associated with sexual function scale score
Adj Coef. P 95 % CI
Age −0.47 <0.001 −0.62 −0.31
Gender Male Ref
Female 2.06 0.24 −1.361 5.48
Marital status Married/cohabiting/ partnered Ref
Single 7.95 <0.001 3.64 12.25
Separated/divorced/ widower 12.56 <0.001 7.99 17.14
Employment status Employed full or part time Ref
Student or stay at home carer −1.51 0.501 −5.92 2.89
Unemployed 1.27 0.637 −4.02 6.57
Retired due to age or disability −5.19 0.007 −8.98 −1.40
Level of disability No or some disability Ref
Gait/cane disability −6.25 <0.001 −9.55 −2.94
Major mobility support −5.91 0.032 −11.31 −0.51
Clinically significant fatigue No Ref
Yes −5.41 0.001 −8.57 −2.26
Depression screen Negative Ref
Positive −13.77 <0.001 −17.41 −10.14
Prescription anti-depressant use Yes −9.40 <0.001 −12.74 −6.06
No Ref
Physical activity Low active Ref
Moderate active 3.11 0.07 −0.19 6.41
High active 4.11 0.024 0.54 7.67
N = 1756, F(14, 1741) = 31.01, p < =0.001, Adj R-squared = 0.1932
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intercourse, number of pregnancies and number of chil-
dren [16, 19, 20]. While age, marital status, level of edu-
cation, employment status, number of children, and
level of disability were associated with our sexual health
outcomes, we did not find an independent association of
gender or medication use in our data.
There is potential for a lifestyle risk factor modifica-
tion approach to the management of SD in PwMS, given
the strong associations of better lifestyle behaviours with
reduced depression risk [33] and fatigue [32], both
known to adversely affect sexual function [22]. In type 2
diabetes, another chronic disease with strong lifestyle as-
sociations, intensive lifestyle intervention in obese
women resulted in a significantly greater proportion
remaining sexually active, improvements in sexual func-
tion, and greater likelihood of remission of SD at 1 year
[43]. Lifestyle approaches to management of SD in
PwMS are however uncommon, and there is little sup-
porting research.
Given the important role of depression in SD, our data
suggest that a more holistic approach to the manage-
ment of depression in PwMS is required. This is particu-
larly important given the associations we have
demonstrated of antidepressant use with SD, sexual sat-
isfaction and overall sexual function. Others have previ-
ously called for judicious use of antidepressant
medication on a background of routine use of lifestyle
modification for the treatment of depression [44]. A
drug-only approach to management of depression in
PwMS appears a poor therapeutic approach. Attention
to lifestyle risk factors, psychosocial interventions and
psychological therapy may decrease depression risk in
their own right but also increase sexual satisfaction [45].
From a practical viewpoint, PwMS often have worse fa-
tigue and particularly low energy in the afternoon and
night time, increasing the likelihood of SD and avoid-
ance of sexual activities. On this basis, PwMS may also
be advised to engage in sexual activity earlier in the day
to reduce SD due to fatigue [41].
Limitations
All data in our study were self-reported, and therefore
were unable to be verified, although previously validated
tools were used where possible. We did not measure the
presence of depression directly, but screened for depres-
sion risk. SD was determined by categorising partici-
pants in two groups depending on their responses to
items on the sexual function scale of the MSQOL-54;
this method has not previously been used or validated,
but does allow for future studies to directly compare
data with ours. Participants were English speaking and
able to complete the survey online, and most were
young women. This sample may therefore not be
generalizable to all PwMS, despite the variety of
backgrounds of participants and size of the sample. Fi-
nally, our study examined associations and is cross-
sectional, hence we cannot assert causality.
Conclusions
Our data confirm that SD is common in the MS popula-
tion, associated with decreased satisfaction with sexual
function. Sexual function and dysfunction for PwMS
have very complex determinants, related to an interplay
of individual, lifestyle and disease characteristics,
strongly influenced by the presence of depression, anti-
depressant use and fatigue. The modifiable factors phys-
ical activity and diet were associated with sexual
function and satisfaction after adjusting for relevant
other variables, raising potential for secondary preven-
tion. Further research should confirm the nature of the
associations of modifiable factors identified in this study,
as well as the drivers of fatigue and depression for
PwMS, as this may assist in improving SD.
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